| Hazard Information | Back Directory | [Description]
AFG210 is a novel first-generation “type II” FLT3 inhibitor. | [Uses]
AFG210 is a potent multi-target kinase inhibitor that primarily inhibits Abl kinase (IC50=330 nM), and also has inhibitory effects on other kinases such as B-Raf, C-Raf, FGFR-1, RET and VEGF receptors. AFG210 can be used to study chronic myeloid leukemia and other diseases with abnormal activation of Abl kinase[1]. | [References]
[1] AC Backes, et al. Small-molecule inhibitors binding to protein kinase. Part II: the novel pharmacophore approach of type II and type III inhibition. Expert opinion on drug discovery, 3(12), 1427-1449. DOI:10.1517/17460440802580106 |
|
| Company Name: |
BOC Sciences
|
| Tel: |
1-631-485-4226; 16314854226 |
| Website: |
https://www.bocsci.com |
|